|
US662510A
(en)
|
1899-05-20 |
1900-11-27 |
Western Electric Co |
Incandescent-lamp socket.
|
|
CH646696A5
(de)
|
1980-11-28 |
1984-12-14 |
Sandoz Ag |
Dibenzazepine, ihre herstellung und verwendung.
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
NZ513144A
(en)
|
1999-02-05 |
2003-05-30 |
Samsung Electronics Co Ltd |
Image texture retrieving method and apparatus thereof
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
JP2003520266A
(ja)
|
2000-01-24 |
2003-07-02 |
メルク シャープ エンド ドーム リミテッド |
γ−セクレターゼ阻害薬
|
|
GB0005251D0
(en)
|
2000-03-03 |
2000-04-26 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
GB0008710D0
(en)
|
2000-04-07 |
2000-05-31 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
CA2427206C
(en)
|
2000-11-02 |
2011-06-28 |
Merck Sharp & Dohme Limited |
Sulfamides as gamma-secretase inhibitors
|
|
US7468365B2
(en)
|
2000-11-17 |
2008-12-23 |
Eli Lilly And Company |
Lactam compound
|
|
UA77165C2
(en)
|
2000-11-17 |
2006-11-15 |
Lilly Co Eli |
(n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
|
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
|
GB0223038D0
(en)
|
2002-10-04 |
2002-11-13 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
GB0223039D0
(en)
|
2002-10-04 |
2002-11-13 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
GB0225474D0
(en)
|
2002-11-01 |
2002-12-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
WO2004110350A2
(en)
|
2003-05-14 |
2004-12-23 |
Torreypines Therapeutics, Inc. |
Compouds and uses thereof in modulating amyloid beta
|
|
GB0326039D0
(en)
|
2003-11-07 |
2003-12-10 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
MX2007000998A
(es)
|
2004-07-30 |
2007-07-11 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
PT2099823E
(pt)
|
2006-12-01 |
2014-12-22 |
Seattle Genetics Inc |
Agentes de ligação ao alvo variantes e suas utilizações
|
|
US8377886B2
(en)
|
2007-09-14 |
2013-02-19 |
Albert Einstein College Of Medicine Of Yeshiva University |
Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
|
|
WO2009135181A2
(en)
|
2008-05-02 |
2009-11-05 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
CN102149825B
(zh)
|
2008-07-08 |
2015-07-22 |
Abbvie公司 |
前列腺素e2双重可变结构域免疫球蛋白及其用途
|
|
WO2011028811A2
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
BR112012008833A2
(pt)
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP3252072A3
(en)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
WO2015120065A1
(en)
|
2014-02-05 |
2015-08-13 |
The Trustees Of Columbia University In The City Of New York |
Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides
|
|
CN106488775A
(zh)
|
2014-07-11 |
2017-03-08 |
基因泰克公司 |
Notch途径抑制
|
|
TWI703159B
(zh)
*
|
2015-04-13 |
2020-09-01 |
美商輝瑞股份有限公司 |
Bcma特異性治療性抗體及其用途
|
|
CA3004152C
(en)
|
2015-11-03 |
2024-04-16 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-cd38 antibodies and their uses
|
|
CN108778329B
(zh)
|
2016-02-17 |
2022-09-16 |
西雅图基因公司 |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
US10307388B2
(en)
|
2016-12-29 |
2019-06-04 |
The United States Of America As Represented By The Secretary Of The Navy |
Compositions and methods for diagnosis and treatment of inflammation
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US11970542B2
(en)
|
2017-11-08 |
2024-04-30 |
Fred Hutchinson Cancer Center |
Bispecific antibodies specific for treating hematological malignancies
|
|
EP3801551A4
(en)
|
2018-05-24 |
2022-04-06 |
Ayala Pharmaceuticals Inc. |
COMPOSITIONS WITH BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND IMMUNOTHERAPEUTICS AND METHODS OF USE THEREOF
|
|
KR102870868B1
(ko)
|
2018-06-01 |
2025-10-15 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
US11773369B2
(en)
|
2018-08-03 |
2023-10-03 |
The Regents Of The University Of California |
Generation of human spinal cord neural stem cells
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
WO2020212914A1
(en)
|
2019-04-19 |
2020-10-22 |
Janssen Biotech, Inc. |
Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses
|
|
PL4010322T3
(pl)
|
2019-08-09 |
2026-02-16 |
Pfizer Inc. |
Stałe postacie (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaftalen-2-ylo)amino)-n-(1-(2-metylo-1-(neopentyloamino)propan-2-ylo)-1h-imidazol-4-ilo)pentanamidu i ich zastosowanie
|